Targeting HER2 beyond progression in gastroesophageal cancer
Mené sur 415 patients atteints d'un cancer gastrique ou d'un adénocarcinome de la jonction gastro-œsophagienne HER2+ de stade localement avancé ou métastatique, cet essai de phase II/III évalue l'efficacité, du point de vue de la survie globale, et la toxicité du trastuzumab emtansine en traitement de deuxième ligne
Trastuzumab's success in HER2-positive gastroesophageal cancer, definitively shown in the ToGA trial in 2010,1 marked a turning point for this disease. Trastuzumab was not just the first targeted therapy with proven efficacy, its success was also proof that gastroesophageal cancer molecular subtypes are clinically relevant. Yet despite all the enthusiasm for this drug, trastuzumab's effect on disease control is modest: primary resistance is common and acquired resistance develops quickly
The Lancet Oncology , commentaire, 2016